Public procurement of biologic medicines
Survey findings on national public procurement practices for biological medicines in the EEA.
Brussels, 29 June 2015 – Today, EuropaBio, the European Association for Bioindustries, launches a White Paper on the Public Procurement of Biological Medicines analysing national practices for publicly procuring complex medicines, such as biologics, in Europe.
The paper presents the findings of a survey of EuropaBio member companies about national public procurement practices for biological medicines in the European Economic Area (EEA). Based on the best practices identified, it then provides key recommendations to decision-makers on how to develop tenders in such a way as to foster fair market competition and innovation for industry, while at the same time guaranteeing a high level of care for patients.
“The paper presents the experience of EuropaBio members participating in national public tenders over the last 6-7 years” explains Miriam Gargesi, EuropaBio’s Director for Healthcare Biotechnology. “The case studies illustrate the challenges currently faced by companies when selling licensed biological medicines to public authorities as well as the positive examples of national tenders that have actually enabled industry to provide patients with best available treatments in a timely fashion. The current public debate on access to innovative medicines is focusing a lot on how to speed up pre-approval processes for industry at EU level. Many forget however, that a lot of the challenges for both industry and patients are at local level and have a lot to do with the way public tenders are designed and implemented”.
About Public Procurement
Public procurement is defined in this paper as “buying pharmaceuticals by purchasers like public hospital associations on the basis of a – often strictly defined – tendering procedure with granting of the contract to the pharmaceutical company / importer who offered the best bid”. At EU level, a new package of directives on public procurement was adopted in February 2014 and EU Member States are expected to transpose the new EU rules into national law by April 2016. Recommendations in this White Paper aim to support the relevant national competent authorities in the effective application of the new rules with regard to the healthcare biotech sector.
Read the report on your screen or download a copy below.